Literature DB >> 31831463

Beyond Angiogenesis: Exploiting Angiocrine Factors to Restrict Tumor Progression and Metastasis.

Mahak Singhal1,2,3, Hellmut G Augustin1,2,4.   

Abstract

Looking beyond tumor angiogenesis, the past decade has witnessed a fundamental change of paradigm with the discovery that the vascular endothelium does not just respond to exogenous cytokines, but exerts active "angiocrine" gatekeeper roles, controlling their microenvironment in an instructive manner. While vascular niches host disseminated cancer cells and promote their stemness, endothelial cell-derived angiocrine signals orchestrate a favorable immune milieu to facilitate metastatic growth. Here, we discuss recent advances in the field of tumor microenvironment research and propose angiocrine signals as promising targets of future mechanism-driven antimetastatic therapies, which may prove useful to synergistically combine with chemotherapy and immunotherapy. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31831463     DOI: 10.1158/0008-5472.CAN-19-3351

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  The vascular niche in next generation microphysiological systems.

Authors:  Makena L Ewald; Yu-Hsi Chen; Abraham P Lee; Christopher C W Hughes
Journal:  Lab Chip       Date:  2021-08-16       Impact factor: 7.517

Review 2.  The Role and Mechanism of the Vascular Endothelial Niche in Diseases: A Review.

Authors:  Zhiqiang Lei; Xiang Hu; Yaoqi Wu; Longsheng Fu; Songqing Lai; Jing Lin; Xiaobing Li; Yanni Lv
Journal:  Front Physiol       Date:  2022-04-27       Impact factor: 4.755

3.  Preclinical validation of a novel metastasis-inhibiting Tie1 function-blocking antibody.

Authors:  Mahak Singhal; Nicolas Gengenbacher; Silvia La Porta; Stephanie Gehrs; Jingjing Shi; Miki Kamiyama; Diane M Bodenmiller; Anthony Fischl; Benjamin Schieb; Eva Besemfelder; Sudhakar Chintharlapalli; Hellmut G Augustin
Journal:  EMBO Mol Med       Date:  2020-04-17       Impact factor: 12.137

4.  Emerging paradigms in metastasis research.

Authors:  Ashik Ahmed Abdul Pari; Mahak Singhal; Hellmut G Augustin
Journal:  J Exp Med       Date:  2021-01-04       Impact factor: 14.307

5.  Exosomal miR-205-5p enhances angiogenesis and nasopharyngeal carcinoma metastasis by targeting desmocollin-2.

Authors:  Wenjuan Yang; Shiming Tan; Lixia Yang; Xiaohui Chen; Ruiqian Yang; Linda Oyang; Jinguan Lin; Longzheng Xia; Nayiyuan Wu; Yaqian Han; Yanyan Tang; Min Su; Xia Luo; Yiqing Yang; Lisheng Huang; Zifan Hu; Yi Tao; Lin Liu; Yi Jin; Hui Wang; Qianjin Liao; Yujuan Zhou
Journal:  Mol Ther Oncolytics       Date:  2022-02-15       Impact factor: 7.200

Review 6.  IL-35 Regulates the Function of Immune Cells in Tumor Microenvironment.

Authors:  Kewei Liu; Ai Huang; Jun Nie; Jun Tan; Shijie Xing; Yue Qu; Ke Jiang
Journal:  Front Immunol       Date:  2021-05-21       Impact factor: 7.561

Review 7.  Neoangiogenesis in Melanoma: An Issue in Biology and Systemic Treatment.

Authors:  Davide Quaresmini; Michele Guida
Journal:  Front Immunol       Date:  2020-10-29       Impact factor: 7.561

Review 8.  Notch Signaling Function in the Angiocrine Regulation of Tumor Development.

Authors:  Alexandre Trindade; António Duarte
Journal:  Cells       Date:  2020-11-12       Impact factor: 6.600

9.  TGF-β-induced IGFBP-3 is a key paracrine factor from activated pericytes that promotes colorectal cancer cell migration and invasion.

Authors:  Rocío Navarro; Antonio Tapia-Galisteo; Laura Martín-García; Carlos Tarín; Cesáreo Corbacho; Gonzalo Gómez-López; Esther Sánchez-Tirado; Susana Campuzano; Araceli González-Cortés; Paloma Yáñez-Sedeño; Marta Compte; Luis Álvarez-Vallina; Laura Sanz
Journal:  Mol Oncol       Date:  2020-09-01       Impact factor: 6.603

Review 10.  Control of Tumor Progression by Angiocrine Factors.

Authors:  Elisenda Alsina-Sanchis; Ronja Mülfarth; Andreas Fischer
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.